Penelope Gray

Publikationer
Populärvetenskap och samverkan

Artiklar

Journal article: INTERNATIONAL JOURNAL OF CANCER. 2024;154(9):1537-1548

Scientific approaches toward improving cervical cancer elimination strategies.

Lehtinen M; Bruni L; Elfström M; Gray P; Logel M; Mariz FC; Baussano I; Vänskä S; Franco EL; Dillner J
Journal article: ELIFE. 2023;12:e80905

Cervical cancer screening improvements with self-sampling during the COVID-19 pandemic.

Elfström M; Gray PG; Dillner J
Article: CELL HOST & MICROBE. 2023;31(11):1921-1929.e3

Ecological diversity profiles of non-vaccine-targeted HPVs after gender-based community vaccination efforts.

Pimenoff VN; Gray P; Louvanto K; Eriksson T; Lagheden C; Söderlund-Strand A; Dillner J; Lehtinen M
Article: JOURNAL OF INFECTIOUS DISEASES. 2022;226(7):1195-1199

Head-to-Head Comparison of Bi- and Nonavalent Human Papillomavirus Vaccine-Induced Antibody Responses.

Arroyo Mühr LS; Eklund C; Lagheden C; Eriksson T; Pimenoff VN; Gray P; Lehtinen M; Dillner J
Article: BMJ OPEN. 2021;11(12):e050669

Human papillomavirus vaccine efficacy against invasive, HPV-positive cancers: population-based follow-up of a cluster-randomised trial.

Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Bly A; Gray P; Harjula K; Heikkilä K; Hokkanen M; Karttunen H; Kuortti M; Nieminen P; Nummela M; Paavonen J; Palmroth J; Petäjä T; Pukkala E; Soderlund-Strand A; Veivo U; Dillner J
Article: LANCET INFECTIOUS DISEASES. 2021;21(10):1458-1468

Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials.

Mariz FC; Gray P; Bender N; Eriksson T; Kann H; Apter D; Paavonen J; Pajunen E; Prager KM; Sehr P; Surcel H-M; Waterboer T; Müller M; Pawlita M; Lehtinen M
Article: PLOS MEDICINE. 2021;18(6):e1003588

Human papillomavirus seroprevalence in pregnant women following gender-neutral and girls-only vaccination programs in Finland: A cross-sectional cohort analysis following a cluster randomized trial.

Gray P; Kann H; Pimenoff VN; Eriksson T; Luostarinen T; Vänskä S; Surcel H-M; Faust H; Dillner J; Lehtinen M
Article: INTERNATIONAL JOURNAL OF CANCER. 2020;147(12):3511-3522

Long-term follow-up of human papillomavirus type replacement among young pregnant Finnish females before and after a community-randomised HPV vaccination trial with moderate coverage.

Gray P; Kann H; Pimenoff VN; Adhikari I; Eriksson T; Surcel H-M; Vänskä S; Dillner J; Faust H; Lehtinen M
Article: INTERNATIONAL JOURNAL OF CANCER. 2020;147(2):440-447

Baseline findings and safety of infrequent vs. frequent screening of human papillomavirus vaccinated women.

Louvanto K; Eriksson T; Gray P; Apter D; Baussano I; Bly A; Harjula K; Heikkilä K; Hokkanen M; Huhtinen L; Ikonen M; Karttunen H; Nummela M; Söderlund-Strand A; Veivo U; Dillner J; Elfstöm M; Nieminen P; Lehtinen M
Article: INTERNATIONAL JOURNAL OF CANCER. 2019;145(3):785-796

Occurrence of human papillomavirus (HPV) type replacement by sexual risk-taking behaviour group: Post-hoc analysis of a community randomized clinical trial up to 9 years after vaccination (IV).

Gray P; Luostarinen T; Vänskä S; Eriksson T; Lagheden C; Man I; Palmroth J; Pimenoff VN; Söderlund-Strand A; Dillner J; Lehtinen M
Article: INTERNATIONAL JOURNAL OF CANCER. 2018;142(12):2491-2500

Evaluation of HPV type-replacement in unvaccinated and vaccinated adolescent females-Post-hoc analysis of a community-randomized clinical trial (II).

Gray P; Palmroth J; Luostarinen T; Apter D; Dubin G; Garnett G; Eriksson T; Natunen K; Merikukka M; Pimenoff V; Söderlund-Strand A; Vänskä S; Paavonen J; Pukkala E; Dillner J; Lehtinen M

Alla övriga publikationer

Letter: INTERNATIONAL JOURNAL OF CANCER. 2023;153(6):1313-1315

HPV16 E6-antibody associated risk of oropharyngeal cancer increases by calendar-time: A nested case-control study.

Lehtinen M; Butt J; Gray P; Brenner N; Eriksson T; Lehtinen T; Luostarinen T; Schroeder L; Surcel H-M; Mäkitie A; Pimenoff VN; Waterboer T
Editorial comment: EXPERT REVIEW OF VACCINES. 2022;21(6):735-738

In 30 years, gender-neutral vaccination eradicates oncogenic human papillomavirus (HPV) types while screening eliminates HPV-associated cancers.

Lehtinen M; Gray P; Louvanto K; Vänskä S
Preprint: SSRN ELECTRONIC JOURNAL. 2019

Population-Based Human Papillomavirus Serosurvey Reveals HPV16/18 Herd Effect But No Clear Type-Replacement in Unvaccinated Females 6 Years Post Gender-Neutral Vaccination in a Cluster Randomised Trial

Gray P; Artemchuk H; Pimenoff VN; Eriksson T; Luostarinen T; Vänskä S; Surcel H-M; Faust H; Dillner J; Lehtinen M

Artiklar

Alla övriga publikationer

Nyheter från KI

Kalenderhändelser från KI